LIMN צמיחת רווח נקי למניה השנה Liminatus Pharma

Anticipation of the start of gastric tumor therapy trials defines the market backdrop for Liminatus Pharma (LIMN), while operating losses are already priced in. The year-over-year change in EPS illustrates the current trend, with the latest value recorded as 0.00. Investment protection is provided by patents in narrow niches, while the demand for oncology treatment renders the business insensitive to economic cycles.
פילוחים אנליטיים ודוחות נתונים של חברת Liminatus (LIMN)

This indicator measures the annual growth rate of net earnings per share, reflecting the efficiency of business scaling. By analyzing annual EPS growth, an investor assesses the company's ability to increase the return on capital. For Liminatus Pharma (LIMN), this parameter confirms the monetization of its unique GCC antigen therapy. Inelastic demand for tumor treatment provides absolute pricing power. The stable dynamics of this metric guarantee the business's resilience to inflationary shocks.